Sana Biotechnology Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Sana Biotechnology Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 2.70 $ to 5.90 $ · Last price: 3.10 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Sana Biotechnology Inc SANA | 0.9 | – | -1.1 | – | – | – | 2.0 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 34.9 | 19.6 | 57.0 | 21.8 | 7.3 | 33.4 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | – | -8 | -13 | -0.07 | -14 | -13 | 34 |
| 2019 | 0 | -141 | -131 | -0.70 | -86 | -143 | 415 |
| 2020 | 0 | -286 | -279 | -1.49 | -138 | -421 | 730 |
| 2021 | 0 | -357 | -344 | -2.07 | -251 | 729 | 1,129 |
| 2022 | 0 | -273 | -266 | -1.41 | -290 | 499 | 823 |
| 2023 | 0 | -293 | -283 | -1.46 | -254 | 288 | 565 |
| 2024 | 0 | -273 | -267 | -1.16 | -223 | 251 | 501 |
| 2025 | 0 | -191 | -244 | -0.96 | -144 | 161 | 417 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.21 | – | 15 | – | -321.10 | -47 | -48 |
| 2025: Q1 | -0.21 | – | 0 | – | – | -49 | -49 |
| 2025: Q2 | -0.39 | – | 0 | – | – | -33 | -33 |
| 2025: Q3 | -0.16 | – | 0 | – | – | -29 | -30 |
| 2025: Q4 | -0.23 | – | 0 | -100.00 | – | -33 | -34 |
| 2026: Q1 | -0.17 | – | 0 | – | – | -37 | -38 |
| 2026: Q2 | -0.22 | 43.60 | – | – | – | -33 | -34 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Breakout & Setup
Risk & Weakness
- Bankruptcy Study: Stacked Warning Signals
- Insolvency Radar: Cash Running Low
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.59 | -0.71 – -0.48 | 0 | 11.8% | 4 |
| 12/31/2027 | -0.56 | -0.74 – -0.42 | 0 | 6.1% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% -56.5%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | Patel Dhavalkumar Dhirajlal | EVP, Chief Scientific Officer | Other | 41,158 | 4.11 | 169,159 |
| Aug 26, 2026 | Patel Dhavalkumar Dhirajlal | EVP, Chief Scientific Officer | Other | 125,000 | 0.00 | – |
The company
About the Company
Sana Biotechnology, Inc., ein Biotechnologieunternehmen, konzentriert sich auf den Einsatz technisch entwickelter Zellen als Medikamente in den USA.
- Employees
- 142
- Headquarters
- Seattle, WA
- Address
- 188 East Blaine Street, 98102 Seattle, United States
- Phone
- 206 701 7914
- Website
- sana.com
- IPO Date
- 02/04/2021
- ISIN
- US7995661045
Management
| Name | Title | Birth Year |
|---|---|---|
| Steven D. Harr M.D. | President, CEO & Director | 1970 |
| Brian D. Piper M.B.A. | Executive VP & CFO | 1972 |
| Susan Wyrick | Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting | 1973 |
| Snehal Patel | Senior VP & Chief Technical Officer | – |
| Dhavalkumar D. Patel M.D., Ph.D. | Executive VP & Chief Scientific Officer | 1961 |
| Aaron M. Grossman | Executive VP, Chief Legal Officer & Corporate Secretary | 1972 |
| Debra Wisdom | VP & Head of People | – |
| Gary Meininger M.D. | Chief Medical Officer | – |
| Yuko Soneoka J.D., Ph.D. | Head of Intellectual Property | – |
| John Gerecitano M.D., Ph.D. | Head of Oncology Research & Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.